This study looks at the long-term safety of two medicines called dabrafenib and trametinib. It is for patients who have completed a previous study with these treatments and are judged to benefit from continued use. The trial includes patients with melanoma, lung cancer, and other types of tumors.
This is a Phase 4 trial, which means it is looking at how well the treatments work and their safety over time. The trial is FDA-regulated and aims to include about 100 participants.
Who can join
Adults aged 18 to 100 years can join. This trial is open to both men and women who are currently receiving dabrafenib or trametinib in a previous study. Patients who have had serious side effects from these medicines or whose condition is now available through other means cannot participate. The trial team will confirm eligibility for each patient.
Conditions
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will receive either dabrafenib alone, trametinib alone, or a combination of both medicines. Everyone in the study will get treatment, and they will not be randomly assigned to different groups. The medicines are taken as capsules or tablets, depending on which one is prescribed.
Where
This trial is enrolling at 5 locations. Recruiting sites are listed first.
Honor Health Research Institute
Scottsdale, Arizona
Recruiting
Honor Health Research Institute
Scottsdale, Arizona
Active Not Recruiting
James Cancer Hospital and Solove Research Institute Ohio State
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.